NAV

Picoplatin

Identification

Generic Name
Picoplatin
DrugBank Accession Number
DB04874
Background

Picoplatin is a cytotoxic platinum compound in clinical development for the treatment of patients with solid tumors. It causes apoptosis (cell death) by binding to DNA and interfering with DNA replication and transcription.

Type
Small Molecule
Groups
Investigational
Structure
Similar Structures
Weight
Average: 376.147
Monoisotopic: 374.986878193
Chemical Formula
C6H10Cl2N2Pt
Synonyms
  • (SP-4-3)-Amminedichloro(2-methylpyridine)platinium
  • Picoplatin
External IDs
  • AMD-473
  • AMD473
  • NX 473
  • NX-473
  • ZD-0473
  • ZD0473
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

For the treatment of patients with solid tumors.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Picoplatin is a sterically hindered platinum (II) complex designed to deliver an extended spectrum of anti-cancer activity and overcome platinum resistance.

Mechanism of action

Picoplatin causes apoptosis (cell death) by binding to DNA and interfering with DNA replication and transcription.

TargetActionsOrganism
UDNANot AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
B5TAN0L720
CAS number
181630-15-9
InChI Key
IIMIOEBMYPRQGU-UHFFFAOYSA-L
InChI
InChI=1S/C6H7N.2ClH.H3N.Pt/c1-6-4-2-3-5-7-6;;;;/h2-5H,1H3;2*1H;1H3;/q;;;;+2/p-2
IUPAC Name
platinum(2+) 2-methylpyridine amine dichloride
SMILES
N.[Cl-].[Cl-].[Pt++].CC1=CC=CC=N1

References

General References
  1. Kelland L: Broadening the clinical use of platinum drug-based chemotherapy with new analogues. Satraplatin and picoplatin. Expert Opin Investig Drugs. 2007 Jul;16(7):1009-21. [Article]
PubChem Compound
177358
PubChem Substance
175426881
ChemSpider
154428
Wikipedia
Picoplatin

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
3Unknown StatusTreatmentSmall Cell Lung Cancer (SCLC)1
2CompletedTreatmentSmall Cell Lung Cancer (SCLC)1
2Unknown StatusTreatmentLung Cancer1
1CompletedTreatmentBladder Cancer / Breast Cancer / Colorectal Cancer / Head And Neck Cancer / Lung Cancer / Neoplasms, Gastrointestinal / Ovarian Cancer / Pancreatic Cancer / Prostate Cancer1
1CompletedTreatmentLymphoma / Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility202.0 mg/mLALOGPS
logP1.25ALOGPS
logP0.89Chemaxon
logS0.34ALOGPS
pKa (Strongest Basic)5.81Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count1Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area12.89 Å2Chemaxon
Rotatable Bond Count0Chemaxon
Refractivity28.49 m3·mol-1Chemaxon
Polarizability10.39 Å3Chemaxon
Number of Rings1Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9651
Blood Brain Barrier+0.9764
Caco-2 permeable+0.7284
P-glycoprotein substrateNon-substrate0.7948
P-glycoprotein inhibitor INon-inhibitor0.9923
P-glycoprotein inhibitor IINon-inhibitor0.994
Renal organic cation transporterNon-inhibitor0.8565
CYP450 2C9 substrateNon-substrate0.7671
CYP450 2D6 substrateNon-substrate0.8139
CYP450 3A4 substrateNon-substrate0.7494
CYP450 1A2 substrateNon-inhibitor0.7636
CYP450 2C9 inhibitorNon-inhibitor0.8311
CYP450 2D6 inhibitorNon-inhibitor0.7598
CYP450 2C19 inhibitorNon-inhibitor0.7224
CYP450 3A4 inhibitorNon-inhibitor0.7689
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8801
Ames testNon AMES toxic0.58
CarcinogenicityNon-carcinogens0.835
BiodegradationNot ready biodegradable0.8478
Rat acute toxicity2.1744 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9532
hERG inhibition (predictor II)Non-inhibitor0.9347
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. DNA
Kind
Nucleotide
Organism
Humans
Pharmacological action
Unknown
DNA is the molecule of heredity, as it is responsible for the genetic propagation of most inherited traits. It is a polynucleic acid that carries genetic information on cell growth, division, and function. DNA consists of two long strands of nucleotides twisted into a double helix and held together by hydrogen bonds. The sequence of nucleotides determines hereditary characteristics. Each strand serves as the template for subsequent DNA replication and as a template for mRNA production, leading to protein synthesis via ribosomes.

Drug created at October 20, 2007 11:20 / Updated at January 14, 2023 19:03